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Red tides have been documented on the Gulf
Coast of Florida as early as 1530 (Taylor
1917). They occur almost annually and often
persist for many months (Woodcock 1948).
Red tides are caused by the dinoflagellate
Karenia brevis (formerly Gymnodinium breve
and Ptychodiscus brevis), which produces a
series of polycyclic ethers called brevetoxins
(PbTx) (Davis 1948; Lin et al. 1981; Martin
and Chatterjee 1969; Poli et al. 1986 ). These
events are responsible for ﬁsh, waterfowl, and
marine mammal mortalities (Landsberg,
2002; Landsberg and Steidinger 1998) as well
as for human intoxication. Aerosol forms of
the toxin are produced by wind and wave
action and move inshore, causing transient
respiratory irritation in people that inhale the
toxin (Pierce 1990). Humans can also experi-
ence the more severe symptoms of neurotoxic
shellfish poisoning (NSP) as a result of con-
suming shellﬁsh that have accumulated breve-
toxin (McFarren et al. 1965).
The action of brevetoxins on its pharma-
cologic target, the voltage-sensitive sodium
channel, leads to activation at normal resting
potential and inhibition of inactivation
(Huang et al. 1984; Sheridan and Adler,
1989; Westerfield et al. 1977). However,
before reaching its target tissue, brevetoxin
must be absorbed into the general blood sup-
ply. Administration of [3H]PbTx-3 orally to
rats leads to accumulation of toxin in the
liver, stomach, and intestines (Cattet and
Geraci 1992). Fat-soluble substances, such as
brevetoxins, coalesce into fat droplets in the
stomach and are emulsified into mixed
micelles by the action of bile acids secreted
into the intestine. The mixed micelles are
likely absorbed via phagocytosis by absorptive
cells of the intestinal villi. Toxin then enters
lymph vessels that drain to the subclavian
vein to enter the liver via the portal circula-
tion. In the liver, fat-soluble toxicants are in
part detoxified by a two-step process that
conjugates a polar entity that is released back
into the intestine, where it may be reabsorbed
and eventually eliminated in urine.
Several toxicokinetic studies treating rats
with [3H]-PbTx3 have shown that blood
retains detectable levels of the radioligand
(Benson et al. 1999; Cattet and Geraci 1993;
Poli et al. 1990b). More recently, studies treat-
ing mice, rats, or fish and measuring toxin
using receptor assay and radioimmunoassay
have quantified blood brevetoxin and deter-
mined that substantial levels (20–30 nM) are
retained in all three species (Fairey et al. 2001;
Radwan et al. 2005; Woofter et al. 2003,
2005). These values are approximately one
order of magnitude higher than the concentra-
tion of toxin necessary to activate voltage-gated
sodium channels in nerve, heart, or muscle
(Bottein Dechraoui and Ramsdell 2003).
This indicates that a significant fraction of
brevetoxin is bound to elements in blood,
reducing its availability to be biologically
active at the sodium channel. Brevetoxin, like
other lipophilic agents, is likely to partition to
cellular elements in blood, and brevetoxin
immunoreactivity has been reported in tissue
lymphocytes and macrophages of manatees
poisoned by brevetoxins (Bossart et al. 1998).
Additionally, brevetoxins may associate with
specialized transport proteins in the plasma.
Blood is technically a tissue containing a
ﬂuid matrix known as the plasma. Plasma is a
protein-rich solution containing a diverse
number of proteins that serve a variety of func-
tions, including transport, immune response,
and tissue-to-tissue signaling (Anderson and
Anderson 2002). A primary function of
plasma is the distribution of insoluble sub-
stances through the use of carrier proteins.
Albumin is the most abundant plasma protein
and serves as a low-affinity, high-capacity
binding protein for steroid hormones and
delivers these insoluble substances to target
cells in the peripheral circulation (Kragh-
Hansen 1981). Plasma also includes more
highly specialized binding proteins. Perhaps
best known are the high-afﬁnity binding pro-
teins for sex steroids, thyroid hormones, and
corticosteroids. In addition, the plasma con-
tains a unique lipoprotein transport system for
the precursor of these steroid hormones, cho-
lesterol. Lipoproteins, protein-coated fatty
acid/cholesterol complexes, distribute choles-
terol to tissues and remove cholesterol from
the plasma. 
Plasma carrier proteins are believed to have
evolved, at least in part, to serve a functional
role to bind and transport nonendogenous
hydrophobic substances (Baker 2002). We
examined the binding of brevetoxin to plasma
carrier proteins in mice, looking especially at
lipoproteins, and evaluated the role of
plasma carrier proteins in the distribution of
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We investigated the brevetoxin congener PbTx-3 to determine its distribution among carrier
proteins, including albumin and blood lipoproteins. Using a radiolabeled brevetoxin tracer (PbTx-3),
we found that 39% of the radiolabel remained associated with components in mouse plasma after
> 15 kDa cutoff dialysis. Of this portion, only 6.8% was bound to serum albumin. We also exam-
ined the binding of brevetoxin to various lipoprotein fractions. Plasma, either spiked with PbTx-3
or from mice treated for 30 min with PbTx-3, was fractionated into different-sized lipoproteins by
iodixanol gradient ultracentrifugation. Each fraction was then characterized and quantified by
agarose gel electrophoresis and brevetoxin radioimmunoassay, respectively. In both the in vitro and
in vivo experiments, the majority of brevetoxin immunoreactivity was restricted to only those gradi-
ent fractions that contained high-density lipoproteins (HDLs). Independent conﬁrmation of breve-
toxin binding to HDLs was provided by high molecular weight (100 kDa cutoff) dialysis of
[3H]PbTx-3 from lipoprotein fractions as well as a scintillation proximity assay using [3H]PbTx-3
and puriﬁed human HDLs. This information on the association of brevetoxins with HDLs pro-
vides a new foundation for understanding the process by which the toxin is delivered to and
removed from tissues and may permit more effective therapeutic measures to treat intoxication
from brevetoxins and the related ciguatoxins. Key words: blood, brevetoxin, ciguatoxin, HDL,
lipoprotein, plasma. Environ Health Perspect 113:1491–1496 (2005). doi:10.1289/ehp.8010
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High-Density Lipoproteinsbrevetoxins to target tissues and the elimina-
tion of brevetoxins from the organism. 
Materials and Methods
Brevetoxin mouse plasma spike. Mouse plasma
in EDTA was obtained from Harlan
Bioproducts (Indianapolis, IN). We spiked a
9.991-mL sample of mouse plasma with 9 µL
of 100 µg/mL PbTx-3 to give a concentration
of approximately 100 ng/mL PbTx-3 in the
mouse plasma. This solution was then cov-
ered, vortexed, and stored at 6°C for 2 hr. We
added 2 mL of 60% iodixanol {5,5´-[(2-
hydroxy-1-3 propanediyl)-bis(acetylamino)]
bis [N,N´-bis(2,3-dihydroxypropyl-2,4,6-tri-
iodo-1,3-benzenecarboxamide)]} to the
10 mL spiked mouse plasma and allowed it to
sit for 2 hr at approximately 4°C. All iodixanol
solutions were kept wrapped in aluminum foil
and stored at 4°C. In two ultracentrifuge
tubes, 9% iodixanol solution (5 mL) was
underlayed by 5 mL of the spiked mouse
plasma in iodixanol. We carefully pipetted
5 mL of HEPES buffered saline on top. 
Brevetoxin mouse exposure. We obtained
20 female ICR mice, 18–20 g, from Harlan
Sprague Dawley (Indianapolis, IN). The mice
were kept for 24 hr with food and water given
ad libitum. We injected 10 of the mice
intraperitoneally (ip) with a maximally tolera-
ble dose (310 µg/kg) of PbTx-3 (Calbiochem,
La Jolla, CA) in 3.1% methanol in phosphate-
buffered saline (PBS). The other 10 mice were
injected ip with 3.1% methanol in PBS. The
brevetoxin congener (PbTx-3 was chosen for
these experiments because it is less reactive to
metabolism in rodents than its precursor
(PbTx-2) (Radwan et al. 2005). We based the
30-min time point for blood collection on
previous toxicokinetic experiments to assure
measurable levels of toxin in fractionated
plasma by radioimmunoassay (RIA) (Woofter
et al. 2003). After a 30-min exposure, the
mice were euthanized with carbon dioxide and
exsanguinated via cardiac puncture to the left
ventricle with a heparinized 1-cc syringe. The
blood was collected in two BD Vacutainer
CPT tubes (BD Vacutainer Systems, Franklin
Lakes, NJ). The tubes were centrifuged for
20 min at 2,100 relative centrifugal force. We
then extracted the plasma by pipette and
transferred it to culture tubes. Mice were
treated in accordance with the Guidelines for
the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources
1996), and all possible efforts were made to
reduce animal suffering and to minimize the
number of animals used.
Gradient ultracentrifugation. Two ultra-
centrifuge tubes containing 5 mL of 9% iodi-
xanol solution were underlayed with 4 mL
extracted mouse plasma in 1 mL iodixanol.
Five milliliters of HEPES buffered saline was
carefully pipetted on top. Samples were
centrifuged at 16°C in a Sorvall swinging
bucket rotor (Kendro Laboratory Products,
Asheville, NC) for 51 hr at 160,000 × g
(acceleration and deceleration 8). The tubes
were extracted without shaking after ultra-
centrifugation. We punctured the ultra-
centrifuge tubes 3 cm from the bottom of the
tube and collected 0.5-mL fractions. Fractions
from the spiked mouse plasma tubes were col-
lected in Eppendorf tubes, and fractions from
the injected mice were collected in glass cen-
trifuge tubes.
Agarose gel electrophoresis lipoprotein
analysis. We used a HYDRAGEL LIPO +
Lp(a) K20 gel electrophoresis kit (SEBIA,
Norcross, GA) for fraction characterization.
Stock buffer (75 mL) was diluted in distilled
water to a volume of 1 L. We made the Sudan
black staining solution by adding 80 mL pure
ethanol, 1 mL Sudan black stock solution,
and 70 mL distilled water. This was allowed
to stir gently for 30 min before use. A wash
solution was prepared by diluting 16 mL of
the wash stock solution in distilled water to a
volume of 1 L. We used a destaining solution
of 45% ethanol in water. 
We ﬁlled the HYDRAGEL K20 applicator
wells with 10 µL of lipoprotein fraction; each
applicator was loaded within 2 min. The appli-
cator was lowered onto the applicator carrier
holding the gel and was allowed to rest on the
gel for 7.5 min before being removed and dis-
carded. We placed the gel into a SEBIA K20
electrophoresis chamber and allowed it to run
for 90 min at 50 V. The gels were removed
from the chamber and placed in an 80°C oven
for 6–10 min or until dry. After being allowed
to cool to room temperature, we placed each
gel in a gel holder and immersed it in 50 mL
Sudan black staining solution for 15 min. Each
gel was then placed in 50 mL destaining solu-
tion for 5 min and then immersed in 50 mL
wash solution for 1 min. The gels were dried at
80°C for 6–10 min and visually characterized.
We stored gels for possible later use at approxi-
mately 4°C.
Brevetoxin radioimmunoassay. We per-
formed radioimmunoassays for detecting
brevetoxin using a sheep antisera prepared
against a PbTx-2-fetuin conjugate (Garthwaite
et al. 2001; Woofter et al. 2001). RIAs were
run in 12 × 75 borosilicate glass tubes in PBS
containing 137 mM NaCl, 8 mM Na2HPO4,
1.5 mM KH2PO4, and 2.7 mM KCl (all from
Sigma Chemical Company, St. Louis, MO),
and 0.01% Emulphor-EL 620 (GAF, New
York). The assay tubes consisted of PbTx-3
standard or ultracentrifuged lipoprotein frac-
tion, anti-PbTx antiserum (1:4,000), and
[3H]PbTx-3 (0.4 nM), in PBS (ﬁnal assay vol-
ume of 500 µL). [3H]-PbTx-3 (21 Ci/mmol;
98.7% radiochemical purity by HPLC)
was produced by sodium borohydride reduc-
tion of PbTx-2 by contract with Amersham
Biosciences (Buckinghamshire, UK). An unde-
termined amount of [3H]-PbTx-9 double reac-
tion product is likely present in the above
preparation. The seven PbTx-3 standards
ranged from 0.01 ng/mL to 1,000 ng/mL. We
allowed the PbTx-3 standards and lipoprotein
fractions to preincubate in buffer at room tem-
perature with the anti-PbTx-3 antibody for
1 hr before the [3H]PbTx-3 tracer was added.
The tubes were placed on a shaker (Titramax
100; Heidolph Instruments, Cinnaminson, NJ)
and incubated 1 hr. We added Sac-Cel (Alpco
Diagnostics, Windham, NH) to the assay tubes
and ﬁltered the bound antibody onto 25-mm
glass fiber filters. Each assay tube was then
rinsed with PBS (3 × 2 mL) using a 48-sample,
Semi-Auto Harvester (Brandel, Gaithersburg,
MD). We placed the ﬁlters in 5.0-mL Scinti-
verse (Fisher, Suwanee, GA) and counted the
radioactivity on a Tri-Carb 3100TR Liquid
Scintilation Counter (Packard-PerkinElmer,
Wellesley, MA).
Direct sandwich mouse albumin ELISA.
We used mouse albumin ELISA (enzyme-
linked immunosorbent assay) quantitation kits
(Bethyl Laboratories, Inc., Montgomery, TX)
to quantify the albumin in each lipoprotein
fraction. The plate was coated with a goat anti-
mouse albumin antibody buffer. After a
60-min incubation, the plate was washed and
then blocked with the postcoat solution. After
incubation with the blocking postcoat solution
for 30 min, we added the standard curve
(7.8–10,000 ng/mL plus blank) and samples
(lipoprotein fractions) to the plate and incu-
bated it for 60 min. The samples were then
washed off the plate and the horseradish perox-
idase (HRP)-conjugated detection antibody
(diluted 1:80,000) was added and incubated in
the plate for 60 min. After washing the plate,
we added TMB (3,5,3´,5´-tetramethylbenzi-
dine), which reacts with the HRP to form a
blue end product. We stopped the TMB reac-
tion by adding 2 M H2SO4, which turned the
blue product yellow. We then read the plate on
a FluoStar plate reader (BMG Labtechnologies,
Durham, NC) at 450 nm.
[3H]PbTx-3–plasma albumin binding
study. Puriﬁed mouse albumin (100 mg) was
solubilized in 1X PBS containing 137 mM
NaCl, 8 mM Na2HPO4, 1.5 mM KH2PO4,
and 2.7 mM KCl (all from Sigma Chemical
Company). Each 300-µL 15-kDa molecular
weight Spectra/Pro Float-A-Lyzer dialysis
tube (Spectrum Laboratories Inc., Rancho
Dominguez, CA) contained 282.5 µL of each
albumin solution and 17.5 µL of a breve-
toxin solution. The final concentration in
each tube was 19, 38, and 76 mg/mL albu-
min in PBS, and 42.5 mg/mL albumin in
mouse reference serum (Bethyl Laboratories,
Inc.) with 29.8 ng/mL PbTx-3/[3H]PbTx-3
(32,000 cpm). The dialysis tubes were pre-
pared and dialyzed in 1X PBS for a total of
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bound [3H]PbTx-3 in the dialysis tubes on a
1211 RackBeta Liquid Scintilation Counter
(Wallac-PerkinElmer, Wellesley, MA).
High-density lipoprotein SPA assay. We
modiﬁed high-density lipoprotein scintillation
proximity assay (SPA) kits (Amersham
Biosciences, Piscataway, NJ), using [3H]PbTx-3
as the radioligand, for direct brevetoxin
binding to HDLs. Each experiment was com-
posed of Btest, NSB (nonspeciﬁc binding), and
B0 groups. Every well contained 10 µL
[3H]PbTx-3 (43 nM, 53,000 dpm) tracer and
10 µL SPA beads (poly-L-lysine coated YSi
beads) with a ﬁnal volume of 60 µL. Each Btest
well contained 30 µL PbTx-3 (50 µM), 10 µL
HDL (0.5 mg/mL) in addition to the tracer
and beads. The NSB group contained 40 µL
PBS and no HDL, whereas the B0 group con-
tained 30 µL PBS and 10 µL HDL.
To determine percent inhibition, we used
the following equation:
Percent inhibition SPA = 
Data analysis. We determined all concen-
trations and EC50 (median effective concen-
tration) values using Prism Graph Pad 4.0
(GraphPad Software, Inc., San Diego, CA).
Results
We first determined whether mouse plasma
has high molecular-binding components for
brevetoxins. Mouse plasma and standard con-
centrations of albumin were spiked with
[3H]PbTx-3, and unbound tracer was removed
by 15-kDa molecular weight cutoff dialysis.
Mouse albumin (20–80 mg/mL) retained a
small fraction (< 6.8%) of the radiolabel after
dialysis (Table 1). In contrast, mouse reference
plasma containing 43 mg/mL albumin
retained substantially more (39%) of the radio-
label after dialysis. These results indicated that
the majority of brevetoxin binding in plasma is
to component other than albumin.
We next examined if brevetoxin bound to
lipoproteins in plasma. Mouse plasma was
spiked with PbTx-3 and iodixanol gradient
ultracentrifugation performed to separate
lipoprotein particles based on density. The rel-
ative abundance of HDL and LDL/VLDL in
the iodixanol gradient fractions was deter-
mined by agarose gel electrophoresis. We col-
lected 26 0.5-mL fractions between the
platelets and chylomicron bands. Fractions 1
and 2 had exclusively HDL, and fractions
3–20 showed decreasing HDL levels and
increasing LDL/VLDL levels; fractions 21–26
had exclusively LDL/VLDL. Analysis of each
fraction by radioimmunoassay indicated that
the most dense lipoprotein fractions, those
containing only HDLs, contained the greatest
amount (85%) of brevetoxin immunoreactiv-
ity within the lipoprotein fractions (Figure 1).
We then examined the lipoprotein frac-
tions to determine whether they may have
been contaminated with concentrated levels
of albumin. To determine if the albumin in
these fractions contributed signiﬁcantly to the
binding of brevetoxin, each fraction was ana-
lyzed for the presence of mouse albumin
using ELISA. Low but detectable albumin
was present in some of the fractions, and dis-
tribution between fractions paralleled the dis-
tribution of brevetoxin (Figure 2). The total
amount of albumin in the ﬁrst two fractions
(HDL) was 1.3 mg, a value much lower than
the amount present in plasma (1.3 mg/4 mL
vs. 40 mg/mL). Hence, although there was
some contamination of HDL fractions with
B– N S B B – N S B
B – NSB 100
0t e s t
0
() − () []
() ×
.
Brevetoxin associated with high-density lipoprotein
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Table 1. Association of brevetoxin to mouse albumin
and plasma. 
Albumin PbTx-3
Sample (mg/mL) (% bound)
Mouse albumin 76 5.0
Mouse albumin 38 6.8
Mouse albumin 19 2.9
Reference plasma 43 38.7
Mouse plasma and different concentrations of mouse albu-
min were spiked with [3H]PbTx-3, and bound PbTx-3 was
separated by 15 kDa molecular weight cutoff dialysis.
Values are from individual sample dialysis bags that were
analyzed in quintuplicate, with SEM < 5%.
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Figure 1. RIA determination of brevetoxin in lipoprotein fractions of spiked mouse plasma. Mouse plasma
was spiked in vitro with PbTx-3 (100 ng/mL), and lipoprotein fractions were collected after iodixanol den-
sity gradient ultracentrifugation. RIA results are given as PbTx-3 equivalents (ng)/fraction and are mean
± SD from a single experiment.
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Figure 2. Determination of albumin in lipoprotein fractions of mouse plasma using direct sandwich ELISA.
Results are shown as albumin (ng)/fraction and are mean ± SD from a single experiment. albumin, it was far less than could be
accountable for brevetoxin binding.
An independent approach was also taken to
assure that the brevetoxin binding to the HDL
fractions was not the result of other plasma car-
rier proteins. Each lipoprotein fraction, prein-
cubated with [3H]PbTx-3, was dialyzed against
a high molecular weight (100 kDa) cutoff
membrane. The two homogenous HDL frac-
tions once again showed the majority of bind-
ing of the lipoprotein fractions (Figure 3). This
dialysis also permitted analysis of the platelet
and chylomicron fractions for brevetoxin bind-
ing, and approximately 25% of the binding was
to platelets and 2.5% was to the chylomicron
fractions.
We conﬁrmed our results using an HDL
SPA. After incubating 6.5 pmol [3H]PbTx-3
with 5 µg purified human HDL under non-
disturbed equilibrium conditions, 0.069 ±
0.015 fmol [3H]PbTx-3 bound per microgram
of HDL. The binding of brevetoxin to HDL
was reversible and saturable, as it was inhibited
by 40% ± 7% in the presence of 50 µM unla-
beled PbTx-3.
The ﬁnal experiment was to expose mice
in vivo to PbTx-3 to compare the distribution
of brevetoxin in lipoproteins from our in vitro
results to an in vivo exposure. Mice were
treated ip with 310 µg/kg PbTx-3 for 30 min
and their plasma was pooled. The plasma
lipoproteins were separated and analyzed by
RIA as described for the experiment presented
in Figure 1. High levels of brevetoxin were
found in the first two fractions containing
exclusively HDLs, with decreasing levels of
brevetoxin paralleling the decreasing levels of
HDLs in fractions 3–11 (Figure 4). Substantial
brevetoxin immunoreactivity was also associ-
ated with the platelet fraction.
Discussion
Binding to plasma/albumin. Previous studies
from our laboratory have found that breve-
toxin achieves levels in whole blood more than
a magnitude higher than its effective intrinsic
concentration (i.e., the concentration required
to bind voltage-gated sodium channels in
nerve, muscle, or heart) (Woofter et al. 2003).
Brevetoxin blood values remain between 25
and 30 nM for the ﬁrst 12 hr in mice, whereas
brevetoxin is effective at approximately
1–5 nM at site 5 of the voltage-gated sodium
channel. This suggests that the majority of
brevetoxin in blood may not be immediately
biologically available and may be bound to cel-
lular elements in blood or the ﬂuid matrix (i.e.,
plasma). Because plasma contains specialized
carrier proteins that may serve to transport
brevetoxin to tissues, our investigation has
focused on brevetoxin distribution in plasma.
Dialysis of [3H]PbTx-3 spiked plasma revealed
that 39% of the radiolabel was retained by
plasma fractions of > 15 15kDa molecular
weight. Of this, only < 6.8% of the binding
was accounted for by binding to albumin
(43 mg/mL) under these conditions. Albumin
is a common binding protein for lipophilic
compounds and has a well-characterized
hydrophobic binding pocket. Whether albu-
min represents a greater percentage of binding
under true equilibrium conditions in plasma
cannot be resolved from these experiments;
however, other factors in plasma provide nearly
five times more binding capacity under the
conditions used for this initial experiment.
Binding to high-density lipoproteins.
Lipoproteins are predominantly recognized as
plasma carrier particles for cholesterol and
triglycerides. They are a heterogeneous class of
protein–lipid aggregates traditionally classiﬁed
by particle density and subsequently by apopro-
tein composition. We found that brevetoxin
added to mouse plasma localized to HDL frac-
tions after being puriﬁed by iodixanol gradient
ultracentrifugation and characterized by agarose
gel electrophoresis mobility. Because of some
contamination of albumin from the adjacent
platelet/fibrin fractions, we also confirmed
using high molecular weight dialysis of
[3H]PbTx-3 that the tracer was associated with
plasma components > 100 kDa molecular
Woofter et al.
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Figure 3. Determination of [3H]PbTx-3 association with plasma components with molecular weight > 100 kDa.
ref, reference. Results are given as the percentage of PbTx-3 bound.
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Figure 4. RIA determination of brevetoxin in lipoprotein fractions from mice exposed, in vivo, to PbTx-3.
Mouse plasma was collected and pooled after being injected (ip) with PbTx-3 or vehicle. This plasma was
then fractionated after iodixanol density gradient ultracentrifugation. The RIA results shown here are
given as PbTx-3 equivalents (ng)/fraction and are mean values ± SD from a single experiment.weight. Additionally, we conﬁrmed binding of
[3H]PbTx-3 to human HDL under non-
disturbed equilibrium SPA. 
HDLs are the highest density class of
lipoproteins. They are assembled in the inter-
stitial space from aggregation of free phospho-
lipids, cholesterol, and apo A1 proteins as
discoidal “nascent” HDL particles. These par-
ticles then serve as a substrate for lecithin:cho-
lesterol acyltransferase, leading to the
esterification of cholesterol. The cholesterol
ester localizes as an inner core and forces the
HDL particles to form spheres, known as
HDL3. The maturation of HDL3 to HDL2
results from the transfer of phospholipids, free
cholesterol, and apoproteins, released from the
lipolyzed VLDLs, to the HDL particle
(Eisenberg 1984). These HDL2 particles are
taken up by the liver and release cholesterol by
a process known as reverse cholesterol trans-
port. Hence, each class of HDL is composed
of a phospholipid, cholesterol, and lipoprotein
A1 outer membrane that successively accumu-
lates triglycerides and cholesterol esters in an
expanding inner core. The process by which
HDLs accumulate cholesterol, ﬁrst described
by Bailey (1965), is the initial step (cholesterol
efflux) of reverse cholesterol transport
(Glomset 1973). This process is still not fully
resolved; however, at least three separate
mechanisms play a role in the uptake of cho-
lesterol by HDL. The ﬁrst mechanism is pas-
sive diffusion of cholesterol, which is a simple
equilibrium of cholesterol between cellular
and lipoprotein compartments. This process is
not restricted to HDL, but is also operative for
LDL and plasma-binding proteins such as
albumin (Zhao and Marcel 1996), yet it is
considered to be particularly well-suited to
mature HDL2 because of the high cholesterol
ester content. The other cholesterol-uptake
mechanisms involve scavenger receptor B1
(SRB1) and the ATP-binding cassette subfam-
ily, A member 1 (ABCA1) transporter.
Binding to low-density lipoproteins. Our
data indicate that brevetoxin binds predomi-
nantly to the HDL class of lipoproteins in
mouse plasma. However, this probably does
not reflect the situation in other species,
including humans, because mice, unlike nor-
molipidemic humans, have small amounts of
VLDLs and LDLs (as low as 20% vs.
70–80%, respectively) in the total lipoprotein
pool (Grass et al. 1995). The low levels of
VLDLs and LDLs present in mouse plasma
may have reduced our ability to detect more
substantial brevetoxin binding to these
lipoprotein classes. Studies with several differ-
ent classes of hydrophobic drugs, including
cyclosporine A, amphotericin B, and nystatin,
indicated that binding occurs to HDLs as
well as to VLDLs and LDLs under in vitro
conditions (Brajburg et al. 1984; Lemaire and
Tillement, 1982; Wasan and Cassidy 1998).
The mechanism for brevetoxin uptake under
these conditions is also consistent with the
passive diffusion of cholesterol. Certain drugs
show a preference for HDL among the
lipoproteins; however, this may be due to the
high protein:lipid ratio of HDL (Cassidy et al.
1998; Kennedy and Wasan 1999; Wasan et al.
1997). Further studies will be needed with
brevetoxins to determine the degree of selec-
tivity for the toxin to the different lipoprotein
classes, with particular reference to lipoprotein
proﬁles representative of human plasma. 
Functional signiﬁcance of brevetoxin bind-
ing to HDL. PbTx-3 administered systemically
to mice distributed to HDL fractions, indicat-
ing that brevetoxin binding to HDL may have
physiologic signiﬁcance. Under in vivo condi-
tions, passive diffusion mechanisms likely play
an important role in the uptake of brevetoxins
to HDL. However, brevetoxins may also utilize
two other mechanisms for cholesterol efflux.
The ﬁrst is SRB1-facilitated aqueous diffusion
of cholesterol (Acton et al. 1996), a process
that appears to involve the reorganization of
membrane lipid domains that transfers choles-
terol to various classes of lipoproteins (Rhainds
and Brissette 2004). The second is the ABCA1
transporter, originally identified as a genetic
defect in Tangier disease (Lawn et al. 1999).
Regardless of the mechanism of brevetoxin
uptake, hepatocytes would then promote trans-
formation, conjugation, and reabsorption of
brevetoxin into the bile. Excretion of a more
polar metabolite would favor intestinal reab-
sorption and excretion via the kidneys into the
urine. Recent studies have indicated that
PbTx-2, the nonreduced precursor of PbTx-3,
is particularly sensitive to transformation and
conjugation in rats and is eliminated rapidly in
the urine (Radwan et al. 2005) and hence
would be a candidate to use this pathway.
Basis for susceptibility and strategies for
therapeutics. The distribution of brevetoxins to
lipoproteins may also indicate a basis for sus-
ceptibility in human populations, based on
blood cholesterol-containing lipids. Indeed,
studies with other compounds that bind to
lipoproteins in plasma have shown that dyslipi-
demia alters drug distribution and enhances
toxicity (Wasan and Cassidy 1998). In this
regard, the distribution of brevetoxins by ip
toxin exposure is not likely to reﬂect distribu-
tion of toxin by oral exposure, as was demon-
strated for chlorpromazine and imipramine
(Bickel 1975). After oral exposure, it is likely
that absorption of brevetoxins across the
intestinal mucosa will lead to their incorpora-
tion into chylomicrons. This may provide an
important immediate distribution mechanism
into the bloodstream and peripheral cells and
then uptake by HDL or possibly LDL by one
of the above-mentioned mechanisms of choles-
terol efﬂux. Accordingly, lipoprotein proﬁle or
genetic variation in several of the mechanisms
for reverse cholesterol transport (SRB1,
ABCA1) may be expected to alter brevetoxin
toxicokinetics and hence sensitivity to toxicity.
Likewise, each of these pathways may provide a
means for potential therapeutic intervention of
brevetoxin in neurotoxic shellfish poisoning
and the more prolonged effects of related poly-
ether ciguatoxin for ciguatera ﬁsh poisoning.
Indeed, the plasma levels of these toxins
remain elevated (Bottein Dechraoui et al.
2005; Radwan et al. 2005; Woofter et al.
2003) and hence are continuously undergoing
enterohepatic recirculation and intestinal reab-
sorption. In this light, another potential target
for therapeutics is the enterohepatic recircula-
tion pathway. Through the binding of bile salts
and reduced intestinal reabsorption, bile acid
sequestrants effectively disrupt this pathway
and have been reported to reduce the symp-
toms of ochratoxin (Kerkadi et al. 1998,
1999). Accordingly, targeting both pathways
for reverse cholesterol transfer and entero-
hepatic recirculation may ultimately lead to the
development of therapies to mitigate the symp-
toms of neurotoxic shellfish poisoning and
ciguatera ﬁsh poisoning.
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